PostEra
PostEra is an AI-driven biopharmaceutical company that uses its Proton machine learning platform to accelerate medicinal chemistry, running co-discovery partnerships with major pharmaceutical companies (Pfizer, Amgen, NIH) and a wholly-owned women's health pipeline.
- Company typePrivate
- Founded2019
- HeadquartersBoston, United States
- Headcount11–50
- GTM typeB2B
- OfferingSoftware
What PostEra does
PostEra is an AI-driven biopharmaceutical company headquartered in Boston, Massachusetts, founded in 2019 by Aaron Morris (CEO), Alpha Lee (CSO), and Matthew Robinson (CTO). The company has developed Proton, an end-to-end machine learning platform for medicinal chemistry that closes the Design-Make-Test cycle. Proton combines proprietary chemistry data with chemistry foundation models to design molecules, employs state-of-the-art synthesis planning to ensure every designed molecule has a reliable synthetic route, and uses novel active learning methodologies to select the most informative experiments at each cycle. A reported 40% faster stage-gate achievement on a Pfizer AI Lab program indicates the platform can materially compress medicinal chemistry timelines.
PostEra commercializes Proton through two channels. First, it runs co-discovery partnerships with major pharmaceutical companies — notably Pfizer (AI Lab formed 2021, expanded to $610M in 2025 including ADC programs), Amgen (multi-program agreement, contributing to over $1B in cumulative AI drug discovery partnerships), and NIH ($68M antiviral grant) — where the partner selects biological targets and PostEra drives discovery through Development Candidate nomination. Second, PostEra advances a wholly-owned preclinical pipeline in women's health indications including PCOS, reproductive endocrinology, and fertility. The company also led COVID Moonshot, described as the world's largest open-science drug discovery effort.
Revenue mechanics are enterprise-style and milestone-weighted: multi-year contracts with upfront payments, research funding, development/regulatory/commercial milestone payments, and royalties on commercialized products, supplemented by government grant funding such as the NIH antiviral program. Equity capital is modest (a $24M Series A led by Clermont Group in 2021/2022, total disclosed equity around $26M, with Y Combinator as an early backer), while cumulative contracted partnership value exceeds $1 billion.
PostEra firmographics
Firmographics- Name
- PostEra
- Legal name
- PostEra
- Website
- https://postera.ai
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- PostEra is an AI-driven biopharmaceutical company that uses its Proton machine learning platform to accelerate medicinal chemistry, running co-discovery partnerships with major pharmaceutical companies (Pfizer, Amgen, NIH) and a wholly-owned women's health pipeline.
- Ownership category
- akta.pro rank
PostEra industry classification
Industry- Product category
- AI Drug Discovery Platform
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
- akta.pro secondary industry
- Drug Discovery (Target ID/Validation & Hit Discovery) (HLAIALAA)
Keywords
Where PostEra is headquartered
LocationHeadquarters
- HQ city
- Boston
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
PostEra business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- Pharmaceutical Partnerships: Multi-year strategic collaborations with major pharmaceutical companies including Pfizer and Amgen. Revenue comes from upfront payments, research funding, milestone payments (development, regulatory, and commercial), and royalties on approved products. The expanded Pfizer collaboration is valued at $610M including additional programs in antibody-drug conjugates.
- Government Research Grants: NIH-funded research collaboration for antiviral therapeutics. Initial funding of $68 million to identify compounds for key viruses and deliver three IND-ready candidates for rapid clinical evaluation during outbreaks.
- Equity Financing: Venture capital funding including $24 million equity financing led by the Clermont Group. Used to enhance drug discovery programs and develop the AI-driven medicinal chemistry platform.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Multi-year contract | Enterprise pharmaceutical partnerships |
Go-to-market motion1 record
Distribution channels2 records
Marketing channels4 records
PostEra product offering
Product offeringCore offering
PostEra develops and applies Proton, its proprietary end-to-end machine learning platform for medicinal chemistry, to accelerate small molecule drug discovery. Through the platform the company runs co-discovery collaborations with major pharmaceutical companies (Pfizer, Amgen) and government agencies (NIH) and advances a wholly-owned preclinical pipeline in women's health (PCOS, reproductive endocrinology, fertility). Revenue is generated via multi-year partnerships with upfront payments, milestones, and royalties, supplemented by government grants.
Product overview
PostEra operates as an AI-driven biopharmaceutical company built around its Proton Platform—an end-to-end machine learning platform for medicinal chemistry. The company advances drug discovery through two channels: (1) a wholly-owned internal pipeline targeting women's health indications (PCOS, reproductive endocrinology, fertility), and (2) partnered programs with major pharmaceutical companies (Pfizer, Amgen, NIH) using Proton to discover small molecule therapeutics across oncology, obesity, antivirals, and antibody-drug conjugates. PostEra also led COVID Moonshot, the world's largest open-science drug discovery initiative. The company has secured over $1 billion in partnerships and is backed by Y Combinator.
Differentiator
Problem solved
Functional benefit
Products and services
- Proton Platform End-to-end AI platform for medicinal chemistry that closes the Design-Make-Test cycle. Proton combines proprietary data with chemistry foundation models to design molecules, applies state-of-the-art synthesis planning to ensure reliable synthetic routes, and uses active learning methodologies to gather informative data at each cycle. Used by PostEra both to run partnered co-discovery programs with biopharma and to advance the company's internal drug pipeline.
- COVID Moonshot Open-science, community-driven antiviral drug discovery program using PostEra's AI capabilities to crowdsource compound design, synthesis, and testing for COVID-19 therapeutics. Demonstrates the application of Proton outside of conventional biopharma partnerships and produces openly shared data for the research community.
Quantifiable outcome
- One AI Lab program achieved its first scientific stage gate 40% faster than initially forecasted
- +1 more outcomes
Companies that use PostEra
Customer profileNamed customers3 records
Segments3 records
Ideal customer profiles2 records
PostEra technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability6 records
Feature4 records
PostEra partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered flagship, core and minor.
- PfizerflagshipExpanded AI drug discovery collaboration to $610 million total deal value, adding antibody-drug conjugates (ADCs) to the partnership. Includes AI Lab formed in 2021 for multi-target collaboration and additional ADC programs in 2025. PostEra uses its Proton platform to accelerate multiple preclinical drug discovery programs with additional payments and milestones. One program achieved first stage gate 40% faster than forecasted; Pfizer nominated a third target into the AI Lab in 2024.
- AmgencoreMulti-program agreement as part of PostEra's $1 billion+ in AI drug discovery collaborations. Collaboration focused on small molecule drug discovery using PostEra's Proton platform.
- NIH (National Institutes of Health)coreMulti-year AI-driven drug discovery collaboration for antiviral therapeutics with $68 million initial funding. The initiative aims to identify compounds for key viruses and deliver three IND-ready candidates for rapid clinical evaluation during outbreaks.
- Oxford UniversityminorListed as a Drug Discovery Partner on PostEra's website, indicating academic collaboration for drug discovery research.
Scale indicators7 records
Recent moves6 records
Expansion highlights6 records
PostEra competitors and assessment
Company assessmentMarket position
Competitive moat4 records
Key risks5 records
Key highlights6 records
Customer concentration
PostEra social profiles
Digital presencePostEra financial estimates
Financial estimateRevenue estimate
Valuation estimate
PostEra leadership team
Management profileNumber of profiles
Profiles27 records
PostEra funding detail
Funding detailFunding overview
Funding rounds4 records
Investors10 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PostEra M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PostEra
What does PostEra do?
PostEra develops and applies Proton, its proprietary end-to-end machine learning platform for medicinal chemistry, to accelerate small molecule drug discovery. Through the platform the company runs co-discovery collaborations with major pharmaceutical companies (Pfizer, Amgen) and government agencies (NIH) and advances a wholly-owned preclinical pipeline in women's health (PCOS, reproductive endocrinology, fertility). Revenue is generated via multi-year partnerships with upfront payments, milestones, and royalties, supplemented by government grants.
Is PostEra a public or private company?
PostEra is a private company. It is classified as venture growth investor backed and is currently operating.
When was PostEra founded?
PostEra was founded in 2019. It employs 11 to 50 people.
Where is PostEra based?
PostEra is headquartered in Boston, United States, in the North America region.
How does PostEra make money?
Three revenue lines are on record. Pharmaceutical Partnerships are the primary driver. The others are government Research Grants and equity Financing.
Does PostEra have an API?
No public API is recorded for PostEra.
What industry is PostEra in?
PostEra's product category is AI Drug Discovery Platform. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization, with a secondary code of HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery). Its NAICS code is 541714 and its SIC code is 8731.